We tested the ability of Prostate Imaging Reporting and Data System (PI-RADS) score and prostate-specific antigen density (PSAD) in predicting the risk of reclassification during active surveillance. Three hundred eighty-nine patients underwent multiparametric magnetic resonance imaging and subsequent confirmatory or follow-up biopsy. PSAD ≥ 0.20 ng/mL2 may improve predictive accuracy of multiparametric magnetic resonance imaging results for reclassification of patients in active surveillance, whereas PSAD < 0.10 ng/mL2 may help selection of patients at lower risk of harboring clinically significant prostate cancer.
Roscigno, M., Stabile, A., Lughezzani, G., Pepe, P., Galosi, A., Naselli, A., et al. (2020). The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?. CLINICAL GENITOURINARY CANCER, 18(6), 698-704 [10.1016/j.clgc.2020.04.006].
The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M.
;Sironi S.;Da Pozzo L. F.
2020
Abstract
We tested the ability of Prostate Imaging Reporting and Data System (PI-RADS) score and prostate-specific antigen density (PSAD) in predicting the risk of reclassification during active surveillance. Three hundred eighty-nine patients underwent multiparametric magnetic resonance imaging and subsequent confirmatory or follow-up biopsy. PSAD ≥ 0.20 ng/mL2 may improve predictive accuracy of multiparametric magnetic resonance imaging results for reclassification of patients in active surveillance, whereas PSAD < 0.10 ng/mL2 may help selection of patients at lower risk of harboring clinically significant prostate cancer.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
